re: ARRY CC
jq,
There was a heavy, heavy emphasis on 797 on the CC. ARRY is hoping to have a late-breaking abstract accepted for ACR, which is next week, I believe. ARRY is seeing some "disease modification" in its results with the drug and seems to think that a common set of biomarkers can predict which patients will benefit the most. The strategy is an "opiod-replacement strategy"--12-15,000 deaths a year from respiratory problems with opiods and that number is growing--and the FDA is concerned about the problem of opiods and their abuse. They've also seen some relief in cancer patients with bone mets. ARRY wants to out-license world-wide rights. Squarer kept emphasizing the importance of this late-breaker at ACR. He sounded more confidant about partnering the drug.
Bladerunner
Market Data 
Markets 
AI
